
From US$85 (10 mg, ready format). Delivery in 2–4 hours (business hours) in Santo Domingo, free of charge; elsewhere in the Dominican Republic, 6–12 h (RD$400). Times are approximate. Research use only.
Dual GIP/GLP-1 receptor agonist — FDA-approved molecule (Mounjaro/Zepbound) with proven clinical efficacy in body-mass reduction and glycemic control studies (Phase III SURMOUNT-1, NEJM 2022), backed by years of clinical data.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Tirzepatide (LY3298176) is a 39-amino-acid peptide built on the sequence of human GIP, with two aminoisobutyric acid (Aib) residues that shield it from the DPP-4 enzyme and a C20 fatty diacid on lysine 20 that gives it a half-life of about five days. It was the first molecule of the class nicknamed “twincretin”: a single peptide that activates both the GIP and the GLP-1 receptor, with higher affinity for the former.
Its clinical research base is the largest in the catalog. The SURPASS (type 2 diabetes) and SURMOUNT (obesity) programs comprised more than ten Phase 3 trials; SURMOUNT-1 (NEJM, 2022) showed reductions in body weight of up to a fifth of baseline at 72 weeks, and SURMOUNT-5 (NEJM, 2025) compared it head-to-head with semaglutide. On that evidence the FDA approved the molecule as Mounjaro (2022, type 2 diabetes), Zepbound (2023, obesity) and, in 2024, for obstructive sleep apnea associated with obesity.
The most frequent adverse effects in trials were nausea, diarrhea and constipation, mostly during escalation; the drug label additionally carries warnings on pancreatitis, gallbladder disease and use in pregnancy. Two things must be kept apart: the molecule tirzepatide holds regulatory approval as a branded medicine; the material Renova distributes is not that medicine but a research reagent (RUO), verified by an independent laboratory and not suitable for human use.
| Class | Dual GIP / GLP-1 receptor agonist (“twincretin”) |
| Development code | LY3298176 (Eli Lilly) |
| Structure | 39 amino acids (GIP backbone), Aib at positions 2 and 13, C20 fatty diacid on Lys20 |
| CAS | 2023788-19-2 |
| Reported half-life | ≈ 5 days (117 h) — weekly administration in trials |
| Regulatory status | Molecule approved by FDA/EMA as a branded medicine (Mounjaro, Zepbound); the Renova product is RUO |
| Sensitivity | Protect from light and heat; do not freeze the reconstituted solution |
Semaglutide is a selective GLP-1 agonist; tirzepatide also activates the GIP receptor, with higher affinity for the latter. In the head-to-head SURMOUNT-5 trial (NEJM, 2025) the reduction in body weight with tirzepatide exceeded semaglutide's at 72 weeks. Gastrointestinal effects were of similar magnitude.
The FDA approved it as Mounjaro for type 2 diabetes (2022), as Zepbound for obesity (2023) and for obstructive sleep apnea with obesity (2024); the EMA approved it as Mounjaro for both indications. Those approvals belong to the branded medicine, not to the research material Renova distributes.
The C20 fatty diacid attached to lysine 20 binds plasma albumin, which protects the peptide from renal clearance and enzymatic degradation; the two Aib residues block DPP-4. Together they stretch the half-life to about 117 hours, the basis for weekly dosing in the trials.
Ready vials (calibrated solution) in several strengths and lyophilized powder to reconstitute with bacteriostatic water. The presentation selector is in the buy box on this page; the cost-per-mg guide explains how to compare them.
Related reading: Tirzepatide: Dual GLP-1 / GIP Agonist · Tirzepatide vs Retatrutide: Mechanism, Studies and Dose Differences · GLP-1 Agonists: How Incretin Analogs Work · GLP-1s in the Dominican Republic: On the Essential Medicines List, Still Not Covered by Insurers
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
How much does Tirzepatide cost in the DR? The price of every presentation is shown above in US dollars (USD) next to its Dominican peso equivalent (RD$), and it is the same nationwide: in Santo Domingo our own team delivers at no charge (approx. 2–4 business hours); for the rest of the country, RD$400 courier is added (approx. 6–12 business hours). Buying 3 or more units of the same product unlocks volume pricing. To compare presentations, see the cost per mg in the DR.
Zones: Santo Domingo · Santiago · Punta Cana · La Romana
Delivery in Santo Domingo in about 2–4 business hours and nationwide in about 6–12 business hours by courier with tracking (RD$400). Reconstituted compounds travel cold-chain (2–8°C) in thermal packaging.
Yes — the Tirzepatide certificate of analysis (Janoshik Analytical, HPLC + mass spectrometry) is published at renovapeptides.do/en/coa/#coa-tirzepatide-60mg, verifiable by test number.
Orders are confirmed over WhatsApp. Payment: Payment Link (PayPal — card, Apple Pay or Venmo), bank transfer, or pay on delivery in Santo Domingo (cash or transfer on receipt).
There is no minimum order. Automatic cart discounts: same-product volume (3+ units 15%, 5+ 25%, 10+ 40%) and Mix & Match across different products (3+ items 10%, 5+ 15%, 7+ 20%; not applicable to Retatrutide or Tirzepatide). The better of the two applies per product; bacteriostatic water is excluded and promo codes can't be combined.
📖 Full guide: Tirzepatide: Dual GLP-1 / GIP Agonist
Your cart is empty